An observational study in Sickle Cell Disease, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 13 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by St. Jude Children's Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital — 15 open to participants now, 17 under way, none of them phase 3. Anemia, Sickle Cell · St. Jude Children's Research Hospital.
Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, this one is the 5th largest by planned enrollment of the 23 observational ones that give a count, is one of 2 that started in 2020, is one of 23 observational ones, reaches primary completion later than 1 of the 16 other live ones, and was the 33rd registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →15 of the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital are open now, in 2 countries. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in Mozambique
Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
St. Jude Children's Research Hospital · Sites in United States
Ages 10–18 · Women only · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 8–17
St. Jude Children's Research Hospital · Sites in United States
Ages 42 mo–78 mo
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 13 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 352 is above the median of 100 across 297 observational studies indexed under Anemia, Sickle Cell.
Median enrollment 45 across the 22 interventional studies, 88 across the 23 observational. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
4 of the studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03353584St. Jude Children's Research HospitalEffect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease | 2026-11 |
| NCT06477289St. Jude Children's Research HospitalPeripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease | 2027-06 |
| NCT07226219St. Jude Children's Research HospitalMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease | 2027-07-01 |
| NCT05583721St. Jude Children's Research HospitalRelationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this prospective mixed-method interview study are to use semi-structured interviews in parents of sickle cell disease (SCD) patients to describe parental attitudes of research involving genomic sequencing, including concerns about participation and expectations from researchers and second, to use surveys to quantitatively measure genetic/genomic knowledge, trust in health care provider, and literacy/numeracy ability in parents of children with SCD and adolescents with SCD. Secondary objectives are development of a web-based tool about treatment options for SCD that fosters patient-clinician communication and promotes shared decision-making. The web-based tool will undergo usability and pilot testing to ensure it is accessible to families and provide data about strategies for integrating into clinical conversations about treatment options.
Investigators will use the data generated to reduce the risk of misunderstanding about DNA and genetic research and build strong relationships between SCD families and researchers in the future. The project will design educational information and study materials to help parents of children with SCD understand important details about genomic medicine in SCD care.
There is a critical gap in knowledge regarding the attitudes, beliefs, and expectations of parents around clinical research trials involving genomic sequencing of children with sickle cell disease (SCD). SCD primarily affects children of African American (Black) race; institutionally we have found differences in enrollment on genomic sequencing trials (G4K (NCT02530658), PG4KDS) with patients identifying as black more likely to decline enrollment. Enrollment on SCCRIP (NCT02098863), a biobank study for children with SCD is high (92.3%), indicating that potential genomic research does not appear to concern many families with SCD. Given the rising prevalence of clinical research involving genomic sequencing in pediatric SCD, coupled with the increasing likelihood that sequencing will be required for enrollment on therapeutic drug or gene therapy trials, there is a clear need for research to better understand stakeholder concerns and expectations around genomic sequencing in this population.
Parents of children with SCD and adolescent patients will be approached to complete a short survey during a routine clinic visit, in the medicine room or in-patient. Survey questions will be administered at the time of the informed consent conversation. Those who agree will be given a paper survey or an ipad to complete survey items which focus on genetic/genomic knowledge, trust in health care provider, and literacy/numeracy ability in parents of children with SCD and adolescents with SCD. Participants also have the option to have questions read to them or they can take the survey on paper. Completion of the survey is expected to take \< 30 minutes. Patient and parent can complete surveys simultaneously.
Of parents completing surveys, a subset will be approached for a private (in person or virtual) semi-structured interview. Participants willing to be interviewed will be interviewed at either the same study visit or at a future visit if this is more convenient for the participant. The interview guide (member of the study team) will ask questions designed to first assess parental perceptions about clinical research then begin to focus on parental attitudes, beliefs, and expectations around research involving clinical genomics. Interviews will be conducted on-site at St. Jude Children's Research Hospital in a private, quiet area. The interview should last 30-60 minutes and will be audio recorded. Some survey or interview study visits may occur remotely.
Investigators will re-approach 5-15 parents and 5-15 patients (both adolescent and young adult) to review educational materials developed about sickle cell disease treatment options. Additionally, investigators will approach parents of children with SCD as well as young adult patients for pilot testing of the web-based educational tool.
Those who meet the Eligibility criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group 1 (Survey and Interview) Participants only:
Group 2 (Focus Group) Participants only:
Group 3 (Usability and Pilot Testing) Participants only:
Exclusion Criteria (All groups):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 13-18 with aforementioned SCD genotype.
Adult Patient with or Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 16-18 with aforementioned SCD genotype whose parent provides verbal informed consent for focus group participation.
Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 13 and up with aforementioned SCD genotype.
Use of semi-structured interviews in parents of SCD patients to qualitatively describe parental attitudes of research involving genomic sequencing, including concerns about participation and expectations from researchers
Interviews will be audio recorded, transcribed verbatim and analyzed using semantic content analysis to identify common themes
Time frame: Day 1, or at a future visit (up to approximately 1 year)
Use of surveys to quantitatively measure genetic/genomic knowledge, trust in health care provider/researchers, and literacy/numeracy ability in parents of children with SCD and adolescents with SCD.
Patients and parents' demographic characteristics will be collected from the electronic medical record (EMR). Participants will complete various survey instruments designed to measure knowledge and attitudes around genetic testing and biobanks, self-reported literacy and numeracy, and trust in providers. Data will be analyzed quantitatively using descriptive statistics, generalized linear regression models and generalized estimation equations.
Time frame: Day 1
Ran from Dec 2020 to primary completion in Mar 2024, 39 months.
Of 130 non-industry observational studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 109. This study's 39 months is below that.
Counting every sponsor, half of 139 studies reached it within 49 months; a quarter within 24 and three quarters within 109.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → May 2027, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Jude Children's Research Hospital →